Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA Pre-Submission Meetings Being Considered By FDA

Jun 17 2013

• By Derrick Gingery

Related Content

Outgoing OGD Director Outlines Accomplishments During His Tenure

Mar 18 2013

FDA Generics Director’s Departure Shows Why Chemistry Matters

Mar 18 2013

Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model

Oct 01 2012

GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm

Dec 17 2012

ANDA Complete Response Letters To Become Routine In 2012

Oct 10 2011

<em>OxyContin</em>’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

Apr 22 2013

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window